Graviti Bupropion XL 300mg Tablets Recall: Failed Tablet Specifications
Graviti Pharmaceuticals recalls 300mg Bupropion XL tablets due to failed tablet specifications. This Rx-only medication may not meet quality standards. Consumers should contact the manufacturer for details.
Lower-risk recall
Failed Tablet/Capsule Specifications
Contact the company
What happened, in plain English
Graviti Pharmaceuticals is recalling 300mg Bupropion Hydrochloride Extended-Release Tablets (XL) because of failed tablet specifications. This means the tablets may not meet quality standards, which could affect safety and effectiveness. Read more at govinfonow.com/recall/31783-graviti-bupropion-xl-300mg-tablets-recall-failed-tablet-specifications.
Source Summary by GovInfoNow · govinfonow.com/recall/31783-graviti-bupropion-xl-300mg-tablets-recall-failed-tablet-specifications · Updated August 17, 2026 · FDA enforcement record: FDA #D-0037-2026
Cite this page
“Graviti Bupropion XL 300mg Tablets Recall: Failed Tablet Specifications.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31783-graviti-bupropion-xl-300mg-tablets-recall-failed-tablet-specifications. Based on FDA recall #D-0037-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0037-2026%22&limit=1).
Why it’s dangerous
The tablets failed to meet specified quality standards, which could lead to inconsistent drug release or effectiveness. However, the recall does not indicate a risk of serious injury or death in normal use.
Who’s affected
Prescription patients who have the 300mg Bupropion XL tablets from Graviti Pharmaceuticals. Those with the specific batch number BPB124341A are most at risk.
How to tell if you have this one
Check for the product name 'Bupropion Hydrochloride Extended-Release Tablets USP (XL)', 300mg, 30-count bottles, Rx only, with batch number BPB124341A and expiration date 10/2026.
- Brand
Graviti- Category
Drug
What to do — step by step
Contact Manufacturer
Reach out to Graviti Pharmaceuticals for specific instructions on handling the recalled product.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Product was distributed to 1 distributor and 16 wholesalers/pharmacy retailers nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 44 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0037-2026 (September 15, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0037-2026 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.